

COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

DRUG UTILIZATION REVIEW PROGRAM

Virginia Medicaid
Drug Utilization Review (DUR) Board
Quarterly Meeting
2pm
Thursday, August 18, 2011
DMAS Board Room 13th Floor

Draft Agenda

1. Call to Order and Introductions – Geneva Briggs, Chair
2. Minutes
 - a. Approval of Minutes from the May 19, 2011 meeting
3. New Drugs
 - a. Caprelsa® (vandetanib)
 - b. Daliresp® (roflumilast)
 - c. DIFICID® (fidaxomicin)
 - d. Endurant® (relpivirine)
 - e. Fluzone® Intradermal (influenza vaccination)
 - f. Horizant® (gabapentin enacarbil)
 - g. Incivek® (telaprevir)
 - h. Monomine® (coagulation Factor IX, human)
 - i. Nulojix® (belatacept) Injection
 - j. Phoslyra® (calcium acetate)
 - k. Sprix® (ketorolac tromethamine)
 - l. Tradjenta® (linagliptin)
 - m. Viibryd® (vilazodone)
 - n. Victrelis® (boceprevir)
 - o. Xeralto® (rivaroxaban)
 - p. Zutripro® (hydrocodone, chlorpheniramine and pseudoephedrine)
 - q. Zytiga® (abiraterone)
5. ProDUR Reports
 - a. Simvastatin label changes



A xerox  Company

COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

DRUG UTILIZATION REVIEW PROGRAM

4. RetroDUR Reports
 - a. Monthly reviews/rereviews
 - b. Future topics
5. AAP in Children
6. Synagis
7. FFY 2010 CMS Annual DUR Report
8. Glossary
9. Other Business
10. Adjournment



A XEROX  Company